GeneDx Holdings WGS 深 滬
等待開盤 09-24 09:30:00 美东时间
85.20
-5.600
-6.17%
華盛通- 最 高92.8096
- 今 開90.50
- 成交量 104.57万股
- 最 低 84.35
- 昨 收 90.80
- 總市值 25.41亿
- 52周最高 170.87
- 市盈率 靜 --
- 換手率 3.51%
- 52周最低 32.21
- 委 比 45.09%
- 總股本 2982.25万
- 歷史最高 896.94
- 量 比 1.08
- 振 幅 9.32%
- 歷史最低 2.466
- 每 手 1
- 風險率 33.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cathie Wood's weekly recap: buys $25M of CoreWeave, trims $40M in Bitcoin ETF
Cathie Wood’s Ark Invest made several large portfolio moves last week, adding to CoreWeave (CRWV) while increasing exposure to healthcare and trimming positions across crypto, genomics and technology....
09-21 19:05
GeneDx Announces New Data Published In Genetics In Medicine Demonstrating First‑Tier Rapid Genome Sequencing Improves Diagnostic Rates, Patient Outcomes, And Operational Efficiency In Pediatric Care
Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis Children experiencing faltering growth saw striking 63% diagnostic yield GeneDx (NASDAQ:WGS), the leader in rare disease dia...
08-24 20:34
美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
BTIG Reiterates Buy on GeneDx Holdings, Maintains $90 Price Target
BTIG analyst Mark Massaro reiterates GeneDx Holdings (NASDAQ:WGS) with a Buy and maintains $90 price target.
08-04 17:15
CORRECTION: GeneDx Hldgs Q2 Adj. EPS $0.01 Beats $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate
GeneDx Hldgs (NASDAQ:WGS) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.19) by 105.26 percent. This is a 98 percent decrease over earnings of $0.50 per share from the same period last year. The company reported quarterly sales of $114.440 million whi...
08-04 05:31
财报速睇 | GeneDx Holdings Corp. Class A 2026财年Q2营收1.14亿美元，同比增长10.7%；归母净利润亏损0.18亿美元，由盈转亏
华盛资讯8月4日讯，GeneDx Holdings Corp. Class A公布2026财年Q2业绩，公司Q2营收1.14亿美元，同比增长10.7%，归母净利润亏损0.18亿美元，由盈转亏。
08-04 04:45
财报速睇 | GeneDx Holdings Corp. Class A 2026财年Q2营收1.14亿美元，同比增长11.4%；归母净利润亏损0.18亿美元，由盈转亏
华盛资讯8月4日讯，GeneDx Holdings Corp. Class A公布2026财年Q2业绩，公司Q2营收1.14亿美元，同比增长11.4%，归母净利润亏损0.18亿美元，由盈转亏。
08-04 04:32
GeneDx Holdings Affirms FY2026 Sales Guidance of $475.000M-$490.000M vs $478.367M Est
GeneDx Holdings (NASDAQ:WGS) affirms FY2026 sales outlook from $475.000 million-$490.000 million to $475.000 million-$490.000 million vs $478.367 million estimate.
08-04 04:19
美股大行评级 | 康托·菲茨杰拉德大幅上调AMD、英特尔、迈威尔科技、美光、西部数据目标价！Applied、INIO、LFTO、Quantinuum获多家大行首予买入评级
今日重点评级关注：Evercore ISI集团：维持ProQR Therapeutics"跑赢大市"评级，目标价从5美元升至6美元；摩根士丹利：维持霍尼韦尔"标配"评级，目标价从245美元升至490美元
06-30 10:14
美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
